Back to Search
Start Over
Ligand-activation of the adenosine A2a receptors inhibits IL-12 production by human monocytes.
- Source :
-
Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2000 Jan 01; Vol. 164 (1), pp. 436-42. - Publication Year :
- 2000
-
Abstract
- Adenosine (ADO) exerts potent anti-inflammatory and immunosuppressive effects. In this paper we address the possibility that these effects are partly mediated by inhibition of the secretion of IL-12, a proinflammatory cytokine and a major inducer of Th1 responses. We demonstrate that 5'-N-ethylcarboxamidoadenosine (NECA), a nonspecific ADO analogue, and 2-p-(2-carbonyl-ethyl)phenylethylamino-5'-N-ethylcarboxamidoadenos ine (CGS-21680), a specific A2a receptor agonist, dose-dependently inhibited, in whole blood ex vivo and monocyte cultures, the production of human IL-12 induced by LPS and Stapholococcus aureus Cowan strain 1. However, the A1 receptor agonist 2-Chloro-N6-cyclopentyladenosine and the A3 receptor agonists N6-Benzyl-NECA and 1-deoxy-1-[6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-N-methyl-be ta-d -ribofuranuronamide expressed only weak inhibitory effects. On the other hand, NECA and CGS-21680 dose-dependently potentiated the production of IL-10. The differential effect of these drugs on monocyte IL-12 and IL-10 production implies that these effects are mediated by A2a receptor signaling rather than by intracellular toxicity of ADO analogue's metabolites. Moreover, CGS-21680 inhibited IL-12 production independently of endogenous IL-10 induction, because anti-IL-10 Abs failed to prevent its effect. The selective A2a antagonist 8-(3-Chlorostyryl) caffeine prevented the inhibitory effect of CGS-21680 on IL-12 production. The phosphodiesterase inhibitor Ro 20-1724 dose-dependently potentiated the inhibitory effect of CGS-21680 and, furthermore, Rp-cAMPS, a protein kinase A inhibitor, reversed the inhibitory effect of CGS-21680, implicating a cAMP/protein kinase A pathway in its action. Thus, ligand activation of A2a receptors simultaneously inhibits IL-12 and stimulates IL-10 production by human monocytes. Through this mechanism, ADO released in excess during inflammatory and ischemic conditions, or tissue injury, may contribute to selective suppression of Th1 responses and cellular immunity.
- Subjects :
- Adenosine analogs & derivatives
Adenosine antagonists & inhibitors
Adenosine pharmacology
Adenosine physiology
Adenosine-5'-(N-ethylcarboxamide) pharmacology
Caffeine analogs & derivatives
Caffeine pharmacology
Cyclic AMP physiology
Cyclic AMP-Dependent Protein Kinases physiology
Dose-Response Relationship, Immunologic
Female
Humans
Interleukin-10 biosynthesis
Interleukin-10 blood
Interleukin-10 metabolism
Interleukin-12 blood
Ligands
Lipopolysaccharides antagonists & inhibitors
Lipopolysaccharides pharmacology
Male
Monocytes drug effects
Monocytes immunology
Phenethylamines antagonists & inhibitors
Phenethylamines pharmacology
Purinergic P1 Receptor Agonists
Purinergic P1 Receptor Antagonists
Receptor, Adenosine A2A
Receptor, Adenosine A3
Receptors, Purinergic P1 physiology
Signal Transduction drug effects
Adenosine metabolism
Immunosuppressive Agents pharmacology
Interleukin-12 antagonists & inhibitors
Interleukin-12 biosynthesis
Monocytes metabolism
Receptors, Purinergic P1 metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 0022-1767
- Volume :
- 164
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Journal of immunology (Baltimore, Md. : 1950)
- Publication Type :
- Academic Journal
- Accession number :
- 10605040
- Full Text :
- https://doi.org/10.4049/jimmunol.164.1.436